Review Article
Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures
Table 3
Notable COVID-19 vaccine candidates in clinical trial.
| Platform | Vaccine | Company | Stage | Location |
| RNA | mRNA 1273 | Moderna | Phase-I (NCT04283461) | USA | BNT 162 | Pfizer, BioNTech | Phase-I (NCT04380701) | Germany, USA |
| DNA | INO 4800 | Inovio Pharmaceuticals | Phase-I (NCT04336410) | USA | Korean Institute of Health | Phase-I | South Korea |
| Lentiviral | LV-SMENP-DC | Shenzhen Genoimmune Medical Institute | Phase-I (NCT04276896) | China | aAPC vaccine | Shenzhen Genoimmune Medical Institute | Phase-I (NCT04299724) | China |
| Inactivated | PiCoVacc | Sinovac BioTech | Phase-I (NCT04352608) | China | COVID-19 vaccine | Wuhan Institute of Biological Products (Sinopharm) | Phase-I | China |
| Nonreplicating viral vector | ChAdox1 nCoV-19 | University of Oxford | Phase-I (NCT04324606) | UK | Ad5- nCoV | CanSino Biologics | Phase-II (NCT04341389) | China |
| Live attenuated | BCG vaccine | Max Planck Institute | Phase-III | Germany | BCG vaccine | Radboud University | Phase-III | Netherlands | BCG vaccine | Texas A&M University | Phase-IV | USA |
|
|